Back to Search Start Over

Pediatric norovirus GII.4 infections in Nicaragua, 1999-2015

Authors :
Bucardo, Filemon
Reyes, Yaoska
Becker-Dreps, Sylvia
Bowman, Natalie
Gruber, Joann F.
Vinje, Jan
Espinoza, Felix
Paniagua, Margarita
Balmaseda, Angel
Svensson, Lennart
Nordgren, Johan
Bucardo, Filemon
Reyes, Yaoska
Becker-Dreps, Sylvia
Bowman, Natalie
Gruber, Joann F.
Vinje, Jan
Espinoza, Felix
Paniagua, Margarita
Balmaseda, Angel
Svensson, Lennart
Nordgren, Johan
Publication Year :
2017

Abstract

Objectives: Investigate clinical and epidemiological factors of pediatric GII.4 norovirus infections in children with acute gastroenteritis (AGE) in Nicaragua between 1999 and 2015. Methods: We retrospectively analyzed laboratory and epidemiologic data from 1,790 children amp;lt;= 7 years with AGE from 6 hospitals in Nicaragua (n = 538), and 3 community clinics (n = 919) and households (n = 333) in Leon, between 1999 and 2015. Moreover, asymptomatic children from community clinics (n = 162) and households (n = 105) were enrolled. Norovirus was detected by real-time PCR and genotyped by sequencing the N-terminal and shell region of the capsid gene. Results: Norovirus was found in 19% (n = 338) and 12% (n = 32) of children with and without AGE, respectively. In total, 20 genotypes including a tentatively new genotype were detected. Among children with AGE, the most common genotypes were GII.4 (53%), GII.14 (7%), GII.3 (6%) and GI.3 (6%). In contrast, only one (1.4%) GII.4 was found in asymptomatic children. The prevalence of GII.4 infections was significantly higher in children between 7 and 12 months of age. The prevalence of GII.4 was lowest in households (38%), followed by community clinics (50%) and hospitals (75%). Several different GII.4 variants were detected and their emergence followed the global temporal trend. Conclusions: Overall our study found the predominance of pediatric GII.4 norovirus infections in Nicaragua mostly occurring in children between 7 and 12 months of age, implicating GII.4 as the main norovirus vaccine target.<br />Funding Agencies|Swedish Research Council [dnr-348-2011-7420]; Fogarty International Center at the National Institutes of Health [5K01TW008401-04]; University of North Carolina, Institute for Global Health & Infectious Diseases

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1233397628
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1016.j.meegid.2017.10.001